Month: September 2026

BRISBANE, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on September 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

In the aggregate, the two new non-executive employees received options to purchase 275,500 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal to $3.92, which was the closing price of Annexon’s common stock on September 15, 2026, the date of grant, and vest over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1/48th of the shares vesting monthly thereafter, subject to each employee’s continued service through the applicable vesting dates.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.

Investor Contact:

Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com

MIAMI, Sept. 16, 2026 (GLOBE NEWSWIRE) — AerSale Corporation (NASDAQ: ASLE), a leading global supplier of aftermarket commercial aircraft, engines, and proprietary engineered solutions, today announced the lease of a Boeing 757-200PCF aircraft to Jupiter Jet, a Kazakhstan-based cargo airline expanding its regional and international freight operations.

The 757-200PCF offers an ideal combination of payload capability, operating economics and range, making it well suited for express cargo and e-commerce networks throughout Central Asia and neighboring markets. The aircraft will support Jupiter Jet’s continued fleet growth as demand for reliable air cargo capacity continues to increase across the region.

“We are pleased to support Jupiter Jet’s fleet expansion with this Boeing 757 freighter,” said Craig Wright, Senior Vice President & Head of Asset Management. “The 757 remains one of the industry’s most versatile and dependable medium-haul freighters, and this lease demonstrates AerSale’s ability to provide tailored fleet solutions that help operators meet evolving market demand.”

Jupiter Jet has established itself as an emerging cargo operator serving Kazakhstan and surrounding markets, providing flexible freight solutions across Central Asia and beyond. The addition of the Boeing 757 freighter will enhance the airline’s operational capabilities while supporting its long-term growth strategy.

“We are excited to add the Boeing 757 freighter to our fleet through our partnership with AerSale,” said Erik Kozbagarov, Chief Executive Officer of Jupiter Jet. “The aircraft’s performance and economics make it an excellent fit for our expanding cargo network, allowing us to better serve our customers while positioning Jupiter Jet for continued growth.”

AerSale’s aircraft leasing platform provides operators worldwide with flexible fleet solutions backed by the Company’s integrated portfolio of aviation products and services, including aircraft and component maintenance, repair and overhaul (MRO), engine solutions, used serviceable material (USM), and asset management.

About AerSale

AerSale serves airlines operating large jets manufactured by Boeing, Airbus and McDonnell Douglas and is dedicated to providing integrated aftermarket services and products designed to help aircraft owners and operators to realize significant savings in the operation, maintenance and monetization of their aircraft, engines, and components. AerSale’s offerings include Aircraft & Component MRO, Aircraft and Engine Sales and Leasing, Used Serviceable Material sales and internally developed Engineered Solutions to enhance aircraft performance and operating economics (e.g. AerSafe®, AerTrak®, and AerAware™ Enhanced Flight Vision System).

Media:
For more information about AerSale, please visit our website: www.AerSale.com.
Follow us on: LinkedIn | Twitter | Facebook | Instagram

AerSale: Jackie Carlon
Telephone: (305) 764-3200
Email: media.relations@aersale.com

Investor:
AerSale: InvestorRelations@aersale.com

Source: AerSale Corporation

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5b6a14d8-942c-44dd-ae54-84980f05b22a

Shareholders grant the Board discretionary authority to implement a share consolidation of up to 30:1

TORONTO and HAIFA, Israel, Sept. 16, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based regenerative therapies, is pleased to announce the voting results from its annual general and special meeting of the shareholders of the Company (“Shareholders”) held on Tuesday, September 15, 2026 (the “Meeting”). Shareholders voted in favour of each resolution put forth at the Meeting.

Annual General and Special Meeting Results

Capitalized terms used but not otherwise defined in this press release have the meanings ascribed to them in the Company’s management information circular dated August 10, 2026 (the “Circular”). Additional information regarding the Consolidation is contained in the Circular and the Company’s press release dated August 21, 2026.

At the Meeting, there were 33 Shareholders represented in person or by proxy holding 32,963,581 Shares, representing 34.90% of the issued and outstanding Shares as at the record date for the Meeting. Each nominee listed in the Circular was reelected as a director of the Company, the results of which were as follows:

Nominee	Votes For:			Votes Withheld / Abstained:
	Number	%		Number	%
Yoram Drucker	32,187,341	99.96%		12,725	0.04%
Dr. Lior Shaltiel	32,103,881	99.70%		96,185	0.30%
Oded Orgil	30,709,588	95.37%		1,490,478	4.63%
Eyal Gabbai	32,187,566	99.96%		12,500	0.04%
David Stolick	32,178,591	99.93%		21,475	0.07%

In addition, at the Meeting, (i) Shareholders reappointed Ziv Haft, CPA (Isr.), a BDO member firm, as the Company’s auditor for the ensuing year and authorized the Audit Committee of the Board to fix the auditor’s remuneration; (ii) disinterested Shareholders re-approved the Company’s amended and restated omnibus equity incentive plan (the “Plan”); and (iii) Shareholders approved the Consolidation Resolution, each as more particularly set forth in the Circular. The results of such votes were as follows:

Resolution	Votes For:			Votes Withheld / Abstained:			Votes Against:
	Number	%		Number	%		Number	%
Reappointment of Auditor	32,948,451	99.95%		15,130	0.05%		N/A	N/A
Re-Approval of Amended and Restated Omnibus Equity Incentive Plan(1)	24,415,656	99.17%		N/A	N/A		204,410	0.83%
Approval of the Consolidation Resolution(2)	32,175,194	97.61%		N/A	N/A		788,387	2.39%

Notes:

1. Approved by a majority of the votes cast by disinterested Shareholders. 7,580,000 Shares held by persons ineligible to vote on the Plan resolution were excluded from the vote.
2. The Consolidation Resolution was approved by not less than 66⅔% of the votes cast by Shareholders at the Meeting.

“We appreciate the support provided by Shareholders for this enabling step in NurExone’s capital-markets strategy,” said Yoram Drucker, Chairman of the Board. “Approval of the Consolidation Resolution provides the Board with flexibility to evaluate market conditions, trading performance and potential U.S. exchange-listing requirements before determining whether, when and at what ratio to implement the Consolidation.”

Shareholder approval authorizes the Board, in its sole discretion, to implement a Consolidation of up to 30 pre-Consolidation Shares for each one post-Consolidation Share at any time within 36 months following approval of the Consolidation Resolution, subject to acceptance of the TSXV and receipt of all other required approvals. Shareholder approval does not require the Board to proceed, and the Board may revoke the Consolidation Resolution or elect not to implement the Consolidation. Any potential U.S. listing would remain subject to further Board approval, acceptance of the TSXV and the applicable U.S. stock exchange, satisfaction of applicable listing standards, regulatory review, market conditions and receipt of all other required approvals.

If implemented by the Board, the exercise prices and numbers of Shares issuable under the Company’s outstanding options, restricted share units, warrants and other securities exercisable, settleable or convertible into Shares will be proportionately adjusted in accordance with their terms.

Shareholders are not required to take any action at this time. If and when the Board determines to implement the Consolidation, further details regarding the timing, final ratio and mechanics will be announced in a subsequent news release. No fractional Shares will be issued in connection with the Consolidation, and any fractional Share that would otherwise result from the Consolidation will be rounded down to the nearest whole Share, as described in the Circular.

Investor Relations Engagement with Acorn Management Partners

The Company has entered into a non-exclusive professional relations and capital markets consulting agreement with Acorn Management Partners, L.L.C. (“Acorn”), an arm’s-length party based in Alpharetta, Georgia. Acorn provides professional-relations and capital markets services focused on increasing a public company’s visibility within the financial professional community. Under the agreement, Acorn will develop and execute a professional-relations program designed to communicate the Company’s publicly disclosed business, financial and corporate developments to licensed brokers, investment professionals and other market participants in the United States. Services may include preparing and distributing educational materials, facilitating discussions and calls with interested financial professionals, providing ongoing feedback regarding market and professional interest, and delivering periodic activity reports to the Company.

Acorn’s approach is focused on professional education and distribution of the Company’s publicly disclosed investment thesis rather than providing investment recommendations, research ratings or price targets. Acorn’s key personnel for the engagement are John Exley III, Chief Executive Officer, and Gregory Lowe, President.

Subject to acceptance by the TSXV, the agreement has a 12-month term ending September 14, 2027, unless terminated earlier in accordance with its terms. The engagement is a cash-only, fee-for-service arrangement, with Acorn to receive monthly cash compensation with a maximum aggregate base fees of US$180000, plus applicable taxes and approved expenses, payable from the Company’s working capital. Acorn will not receive any securities of the Company as compensation. The Company has been advised that neither Acorn nor its key personnel owns or controls any securities of the Company, presently intends to acquire any such securities or participated in a recent financing of the Company. Acorn will not commence providing services until TSXV acceptance has been obtained.

About Acorn
Acorn Management Partners, LLC is a U.S.-based professional-relations and capital markets firm focused on helping public companies build awareness and strengthen relationships within the financial professional community. Acorn works directly with licensed brokers, investment professionals and other market participants to communicate a company’s publicly disclosed investment thesis, business developments and capital markets strategy. Its model combines professional education, financial communications and broker-focused distribution, with experience supporting small- and mid-cap public companies.

About NurExone
NurExone is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve damage. Regulatory milestones, including obtaining the Orphan Drug Designation, facilitate the Company’s roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top to anchor its North American activity and growth strategy.

For additional information and a brief interview, please watch Who is NurExone?, visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.

For more information, please contact:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com

Russo Partners LLC
Investor and Media Relations – United States
215 Park Ave S, Suite 1905
New York, NY 10003
Phone: 212-845-4200
Email: nurexone@russopartnersllc.com

Dr. Eva Reuter
Investor Relations – Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements are often, but not always, identified by words and phrases such as “may”, “will”, “could”, “would”, “expect”, “intend”, “anticipate”, “believe”, “potential”, “proposed”, “subject to”, “position”, “support” and similar expressions.

Forward-looking statements in this press release include, without limitation, statements relating to: whether the Board will implement the Consolidation; the timing and ratio of any Consolidation; the Board’s evaluation of market conditions, trading performance and potential U.S. exchange-listing requirements; receipt of acceptance of the TSXV and other required approvals; the anticipated effects of the Consolidation on the trading price, marketability and liquidity of the Shares; the Company’s evaluation of a potential listing on a major U.S. stock exchange and the anticipated benefits of any such listing; the adjustment of the Company’s outstanding options, restricted share units, warrants and other securities if the Consolidation is implemented; the commencement, term, performance and anticipated activities of the Company’s engagement with Acorn; the expected scope and potential benefits of Acorn’s investor relations and market-awareness services; and statements in the “About NurExone” section regarding the Company’s development plans, regulatory pathway, clinical-trial roadmap, commercialization strategy and platform opportunities.

Forward-looking statements are based on management’s current expectations, beliefs and assumptions as of the date of this press release, including assumptions regarding: the Board’s ability to select and implement an appropriate Consolidation ratio within the authority approved by Shareholders; prevailing market conditions and the trading price of the Shares; receipt of acceptance of the TSXV and other required approvals; the Company’s ability to satisfy applicable listing requirements if it elects to pursue a U.S. exchange listing; Acorn’s ability to perform the services in accordance with the agreement and applicable requirements; the accuracy and continued relevance of the publicly disclosed information used in connection with Acorn’s services; the continued availability of sufficient capital to pay the costs of the Acorn engagement and advance the Company’s activities; the amount of any reimbursable expenses under the Acorn agreement remaining within the Company’s anticipated budget; and the absence of material adverse changes in applicable laws, exchange requirements, market conditions or the Company’s business.

Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual events or results to differ materially, including, without limitation: the risk that the Board elects not to proceed with the Consolidation or selects a different timing or ratio than anticipated; the risk that required regulatory approvals or acceptance of the TSXV are not obtained; the risk that the Consolidation does not result in a proportionate or sustained increase in the market price of the Shares; the risk that the Consolidation adversely affects trading liquidity or shareholder participation; the risk that the Consolidation does not improve marketability, broaden investor interest or facilitate future financing or capital-markets initiatives; the risk that the Company does not pursue or complete a U.S. exchange listing or satisfy applicable initial or continued listing requirements; the risk that the Acorn engagement does not commence or continue as contemplated; the risk that Acorn’s services do not increase market awareness or result in any anticipated benefit; financing and market risks; regulatory and execution risks; early-stage development risks; the risk that preclinical results are not predictive of clinical outcomes; manufacturing, regulatory, intellectual-property, competition and technological-change risks; and the risks described in the Company’s continuous disclosure filings available under the Company’s SEDAR+ profile at www.sedarplus.ca.

No final decision has been made to implement the Consolidation or pursue any U.S. exchange listing, registration statement, financing or other capital-markets transaction. Any potential U.S. listing would remain subject to further Board approval, applicable Canadian and U.S. regulatory requirements, acceptance of the TSXV and the applicable U.S. stock exchange, satisfaction of all applicable listing standards, market conditions and other customary considerations. There can be no assurance that the Consolidation will be implemented or that any U.S. listing or related capital-markets initiative will be pursued or completed.

Readers are cautioned not to place undue reliance on forward-looking statements. Although the forward-looking statements contained in this press release are based on assumptions that management believes are reasonable as of the date hereof, actual events and results may differ materially. These forward-looking statements are made as of the date of this press release, and the Company undertakes no obligation to update or revise them except as required by applicable law.

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) — Avalyn Pharma Inc. (Nasdaq: AVLN) (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced the appointment of Robert (Bob) J. Meyer, MD, a distinguished pulmonary physician and former senior U.S. Food and Drug Administration (“FDA”) leader, to its Board of Directors (the “Board”). Dr. Meyer most recently served as Principal of Drug and Biologics Products at Greenleaf Health, now Eliquent Life Sciences.

“On behalf of the entire Avalyn team, I am thrilled to welcome Bob to our Board of Directors,” said Lyn Baranowski, Chief Executive Officer of Avalyn. “As an accomplished pulmonologist and regulatory leader who spent decades shaping the development and review of respiratory therapies at both the FDA and Merck, Bob brings a rare combination of clinical, scientific, and regulatory expertise. His firsthand experience evaluating therapies at the FDA and advancing products through global development programs gives him a unique perspective on the regulatory, clinical, and strategic considerations that drive successful drug development. His guidance will be invaluable as we advance AP01, AP02, and our emerging combination therapy candidate AP03 through their next stages of clinical development and execution.”

“Avalyn’s inhaled approach represents a compelling opportunity to address the tolerability challenges that limit the use of current antifibrotic therapies and offer new hope to patients living with pulmonary fibrosis,” said Dr. Meyer. “I am honored to join the Board at this pivotal stage for Avalyn. With multiple programs advancing through development, the Company is well positioned to drive meaningful progress for patients with serious respiratory diseases, and I look forward to supporting its vision of transforming the treatment paradigm for these underserved communities.”

Dr. Meyer brings more than 25 years of leadership experience spanning regulatory, academic, and industry roles. He most recently served as a Principal of Drug and Biologics Products at Greenleaf Health, a leading FDA regulatory consulting firm, advising biopharmaceutical companies on regulatory strategy, clinical development and product approvals. Prior to joining Greenleaf, he served as Director of the Virginia Center for Translational and Regulatory Sciences at the University of Virginia School of Medicine.

Before his academic career, Dr. Meyer spent more than 15 years at the FDA, including serving as Director of the Office of Drug Evaluation II within the Center for Drug Evaluation and Research, where he oversaw the review and regulation of pulmonary and allergy, metabolic and endocrine, analgesic and anesthetic, and rheumatologic drug products. Earlier in his FDA tenure, he served as Director of the Division of Pulmonary and Allergy Drug Products, following roles as a medical reviewer and team leader. He subsequently held senior leadership positions at Merck Research Laboratories, including Vice President, Global Regulatory Strategy, Policy and Safety, where he led worldwide regulatory and pharmacovigilance activities. A board-certified pulmonologist and critical care specialist, Dr. Meyer also brings significant public company and governance experience, having served on the boards of multiple biopharmaceutical companies, including Chimerix, Translate Bio, and Correvio.

About Avalyn Pharma
Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn’s AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF). AP01 has indicated encouraging safety and clinical activity across Phase 1b and multi-year open-label extension trials, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone. Avalyn’s AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF). Avalyn is also advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver multiple antifibrotic mechanisms through a single lung-targeted platform. By leveraging its proprietary drug-device approach and deep expertise in rare respiratory disease development, Avalyn aims to establish a new standard of care in pulmonary fibrosis through inhaled, lung-targeted therapies. For more information, please visit avalynpharma.com and follow the company on LinkedIn.        

Investor Contact:
Cassie Saitow, Avalyn Pharma Inc.
Sr. Director, IR and Corporate Communications
ir@avalynpharma.com

Media Contact:
Precision AQ
avalyn@precisionaq.com

SPRINGFIELD, Mo., Sept. 16, 2026 (GLOBE NEWSWIRE) — The Board of Directors of Great Southern Bancorp, Inc. (NASDAQ:GSBC), the holding company for Great Southern Bank, declared a $0.43 per common share dividend for the third quarter of the calendar year ending December 31, 2026.

The dividend will be payable on October 14, 2026, to stockholders of record on September 28, 2026. This dividend represents the 147^th consecutive quarterly dividend paid by the Company to common stockholders.

About Great Southern Bank

Headquartered in Springfield, Missouri, Great Southern offers a broad range of banking services to customers. The Company operates 87 retail banking centers in Missouri, Iowa, Kansas, Minnesota, and Nebraska and commercial lending offices in Atlanta, Charlotte, Chicago, Dallas, Denver, and Phoenix. The common stock of Great Southern Bancorp, Inc. is listed on the Nasdaq Global Select Market under the symbol “GSBC.”

CONTACT:

Kincade Ayers,
Investor Relations,
(616) 233-0500
GSBC@lambert.com

TORONTO, Sept. 16, 2026 (GLOBE NEWSWIRE) — (TSX: PFIA, PFCO, PFCB, PFAA, PFIG) Picton Mahoney Asset Management (“PICTON Investments”) announced today that it has declared the September 2026 monthly cash distribution of $0.0481 per unit for the ETF units (“ETF Units”) of the PICTON Long Short Income Alternative Fund.

PICTON Investments announced today that it has declared the September 2026 monthly cash distribution of $0.0403 per unit for the ETF Units of the PICTON Credit Opportunities Alternative Fund.

PICTON Investments announced today that it has declared the September 2026 monthly cash distribution of $0.0320 per unit for the ETF Units of the PICTON Core Bond Fund.

PICTON Investments announced today that it has declared the September 2026 monthly cash distribution of $0.0404 per unit for the ETF Units of the PICTON Multi-Strategy Alpha Alternative Fund.

PICTON Investments announced today that it has declared the September 2026 monthly cash distribution of $0.0644 per unit for the ETF units of the PICTON Investment Grade Alternative Fund.

Unitholders of record of the ETF Units, at the close of business on September 22, 2026, will receive a per-unit cash distribution payable on September 30, 2026.

About PICTON Investments

PICTON Investments is a Canadian investment firm with $20.0 billion in assets under management (as at August 31, 2026), recognized for pioneering alternative investment strategies that challenge traditional thinking. Since 2004, we have been helping advisors and investors rethink portfolio construction – moving away from traditional models toward more resilient, diversified solutions. Leveraging deep expertise in quantitative research, fundamental analysis, and authentic hedging strategies, we champion a modern approach designed to deliver more consistent, risk-adjusted returns. Our philosophy is to “Build from the Bear Up,” embracing a bear mindset of resiliency, adaptability, and strength to provide Canadians with greater certainty.

For further information please contact:

Arthur Galloway
Picton Mahoney Asset Management
Tel: (416) 955-4108
Website: www.pictoninvestments.com
Email: invest@pictoninvestments.com

FORT COLLINS, Colo., Sept. 16, 2026 (GLOBE NEWSWIRE) — Woodward, Inc. (NASDAQ:WWD) today announced that its Board of Directors declared a cash dividend of $0.32 per share for the quarter, payable on December 3, 2026, for stockholders of record as of November 19, 2026.

About Woodward, Inc.

Woodward is the global leader in the design, manufacture, and service of energy conversion and control solutions for the aerospace and industrial equipment markets. Our purpose is to design and deliver energy control solutions our partners count on to power a clean future. Our innovative fluid, combustion, electrical, propulsion and motion control systems perform in some of the world’s harshest environments. Woodward is a global company headquartered in Fort Collins, Colorado, USA. Visit our website at www.woodward.com.

Notice Regarding Forward-Looking Statements

The statements in this release contain forward-looking statements that involve risks and uncertainties, including statements concerning the company’s cash dividend. Actual results could differ materially from projections or any other forward-looking statements and we have no obligation to update our forward-looking statements except as required by law. Factors that could affect performance and could cause actual results to differ materially from projections and forward-looking statements are described in Woodward’s Annual Report and Form 10-K for the year ended September 30, 2025, and any subsequently filed Quarterly Report on Form 10-Q.

CONTACT:
Dan Provaznik
Director Investor Relations
970-498-3849
Dan.Provaznik@Woodward.com 

Monthly Highlights

• AI Cloud:
  • Bitdeer AI secured 100% contracted GPU capacity for its 9.5 MW A102 facility in Malaysia ahead of energization through long-term commitments, representing more than $800 million in total expected revenue.
  • Bitdeer has signed a non-binding Letter of Intent to develop an AI data center in Bhutan’s Gelephu Mindfulness City, targeting an initial 30 MW of renewable hydro/solar-powered capacity with a potential expansion pathway to 500 MW.
  • Bitdeer AI executed a 10-year data center services agreement securing an additional 65.1 MW at its A202 facility on the Johor campus, scaling total campus AI Cloud capacity to 86.8 MW to capture high-density compute demand.
• Colocation: Bitdeer recently acquired 200 acres near existing 563 MW Rockdale facility to support AI/HPC infrastructure development.
• Bitcoin: Production increased 249% Y/Y to 1,310 Bitcoins.

Key Metrics Summary
AI Cloud Pipeline (IT MW)		AI Cloud ARR1		Colocation AI Data Center		Self-Mining Hash Rate2		Co-Mining Hash Rate3		BTC Mined
206.5 MW		~$86M		$4.7B, 16-Year Lease with Volta at Tydal, Norway		79.9 (EH/s)		21.6 (EH/s)		1,310

SINGAPORE, Sept. 17, 2026 (GLOBE NEWSWIRE) — Bitdeer Technologies Group (NASDAQ: BTDR) (“Bitdeer” or the “Company”), a world-leading technology company for AI and Bitcoin mining infrastructure, today announced its unaudited operations updates for August 2026.

Management Commentary
“Our AI-cloud strategy continues to validate the vertically integrated model we’ve built at Bitdeer, converting powered land into large-scale, contracted AI/HPC revenue in addition to simply mining Bitcoin,” said Michael G. Potter, Chief Financial Officer of Bitdeer. “Tydal and the full contracting of our A102 facility are proof points that customers value the reliability and scale of our platform.” Mr. Potter continued, “We remain focused on turning that demand into durable, high-margin revenue that complements our mining business, and we’re encouraged by the pipeline of opportunities ahead.”

Bitdeer AI Update:

Colocation AI Data Center:

• Bitdeer recently acquired 200 acres near existing 563 MW Rockdale facility to support AI/HPC infrastructure development. Outright ownership provides the long-term site control required to develop and finance AI/HPC data center infrastructure. Bitdeer believes its Rockdale site, with its existing large-load interconnection and established transmission infrastructure, is well positioned to receive additional power allocations over the coming years.
• Bitdeer announced a 16-Year AI/HPC Data Center Lease for its Tydal, Norway Campus, representing approximately $4.7 billion of total contract value over the initial base term, with the potential to reach a total contract value of approximately $8.0 billion if the tenant exercises its one-time 8-year lease extension.
• Tydal, Norway AI Data Center expected to be among Norway’s largest and most efficient AI data centers upon completion. With a PUE of approximately 1.1 and running on 100% renewable energy, it sets a compelling standard for data center performance, at scale.

AI Cloud Key Metrics: 

Metric	August 2026	July 2026
GPU Amount Deployed	4,328	4,248
GPU Types	H100, H200, B200, B300, GB200, GB300	H100, H200, B200, GB200, GB300
Utilization Rate8	92%	95%
GPUs Under External Subscription	3,998	3,517
ARR1	~$86M	~$76M

AI Cloud Pipeline Update:

Data Center	Location	IT Load (MW)	GPU Platform	DC RFS	Cloud Contract Status	Long Term Contract Coverage, %	DC Contract
A101	Malaysia	2.5	GB200 and GB300	Live	Live	100%	Signed
A102	Malaysia	9.5	GB300	Nov 2026	100% signed	100%	Signed
A201	Malaysia	21.7	GB300 and Vera Rubin	Jan 2027	Late negotiations		Signed
A202	Malaysia	65.1	GB300 and/or Vera Rubin	Q3 2027			Signed
A401	Norway	42.7	Vera Rubin	2H 2027			Self-Owned
A501	WA, USA	10	Vera Rubin	Dec 2027			Self-Owned
A601	TN, USA	55	Vera Rubin	Oct 2027			Self-Owned
Total		206.5

• New AI Data Center site: Bitdeer has signed a non-binding Letter of Intent to develop an AI data center in Bhutan’s Gelephu Mindfulness City, targeting an initial 30 MW of renewable hydro/solar-powered capacity with a potential expansion pathway to 500 MW.
• Full Contracting of A102 Facility (Malaysia): Bitdeer AI secured 100% contracted GPU capacity for its 9.5 MW A102 facility in Malaysia ahead of energization through long-term commitments, representing more than $800 million in total expected revenue. As a general matter, Bitdeer AI seeks to structure its AI Cloud contracts so that customer prepayments are expected to cover approximately 50% of the associated capital expenditure. Revenue recognition is expected to begin in Q1 2027.
• GPU Procurement for A201 Facility: Bitdeer AI advanced hardware readiness for its A201 facility by procuring 133 racks of GB300 ahead of energization at market price from an unaffiliated third-party supplier, ensuring seamless post-energization deployment and rapid time-to-market. This procurement is subject to customary representations, warranties, covenants, indemnities and termination rights.
• Capacity Expansion at A202 Facility (Malaysia): Bitdeer AI executed a 10-year data center services agreement securing an additional 65.1 MW at its Johor campus, scaling total campus AI Cloud capacity to 86.8 MW to capture high-density compute demand.
• Model Service Expansion: The model service onboarded six open-source models in August, including Day-0 availability of NVIDIA Nemotron 3.5 Lightning. These additions reflect our continued investment in the token service, broadening our open-source model offerings while enhancing service stability.
• Industry & Community Engagement: Bitdeer AI expanded its industry reach by participating in Ai4 2026 in Las Vegas, speaking on a panel at SGTech, and hosting developer community events in Singapore to connect with key stakeholders across AI infrastructure, enterprise adoption, and emerging technologies.

Crypto Mining Update:

CRYPTO Mining, R&D, Manufacturing:

• Mined 1,310 Bitcoins⁴, an increase of 249% Y/Y; we continue to expect momentum in our mining results over the coming months.
• Self-mining hash rate reached ~79.9 EH/s.
• Co-mining hashrate of 21.6 EH/s driven by Co-Mining collaboration, using Bitdeer’s mining rigs operated by 3^rd party datacenters.

Key Crypto Metrics:

Metric	August 2026	July 2026	August 2025
Hash Rate Metrics:
Self-Mining (Operated in self-owned datacenters)	79.9	76.7	30.0
Other Proprietary Hash Rate5	4.2	5.0	0.3
Total Proprietary Hash Rate6(EH/s)	84.1	81.7	30.3
Co-Mining (Operated by 3rdparty datacenters)	21.6	18.7	–
BTC Mined4	1,310	1,190	375
BTC Held7	61	257	1,934

Infrastructure Summary:
Bitdeer will transition its infrastructure updates from a monthly reporting cadence to quarterly disclosures issued concurrently with its financial earnings releases, providing a more meaningful and integrated perspective on the Company’s development progress. The Company’s most recent infrastructure update was disclosed alongside its Q2 2026 financial results on August 10, 2026.

Footnotes
¹ ARR as of the last day of the respective month is calculated by multiplying the daily revenue generated from all contractually obligated GPU orders on that specific day by 365. This metric provides an annualized view of the revenue run-rate based on active contracts at the end of the reporting period.
² Self-Mining (Operated in self-owned datacenters) refers to cryptocurrency mining for Bitdeer’s own account, whereby its mining rigs are operated in self-owned datacenters.
³ Co-mining (Operated by 3^rd party datacenters) refers to cryptocurrency mining for Bitdeer’s own account, whereby its mining rigs are operated by third-party datacenters.
⁴ Includes BTC from self-mining operations and BTC from co-mining operations.
⁵ Other Proprietary Hash Rate includes the hashrate from Bitdeer’s cloud hashrate business, mining rigs delivered in the crypto mining datacenters but not deployed and the mining rigs temporarily offline due to limited economic benefit.
⁶ Total Proprietary Hash Rate as of August 31, 2026 includes Self-Mining Hash Rate and Other Proprietary Hash Rate.
⁷ Bitcoins held does not include Bitcoins from customer deposits but does include Bitcoins that are pledged as collateral by us.
⁸ Utilization Rate as of the last day of the respective month is calculated as the total number of GPUs under internal and external orders divided by the total number of deployed GPUs.

About Bitdeer Technologies Group

Bitdeer is a world-leading technology company for AI and Bitcoin mining infrastructure. Bitdeer is committed to providing comprehensive Bitcoin mining solutions for its customers and building AI computational infrastructure to support the AI revolution. Bitdeer handles complex processes involved in computing such as equipment procurement, transport logistics, data center design and construction, equipment management, and daily operations. Bitdeer also offers advanced cloud capabilities to customers with high demand for artificial intelligence. Headquartered in Singapore, Bitdeer has deployed data centers across multiple countries, including the United States, Norway, Bhutan, Ethiopia, and Malaysia. To learn more, visit https://ir.bitdeer.com/ or follow Bitdeer on X@Bitdeer and LinkedIn @Bitdeer.

Investors and others should note that Bitdeer may announce material information using its website and/or on its accounts on social media platforms, including X, formerly known as Twitter, Facebook, and LinkedIn. Therefore, Bitdeer encourages investors and others to review the information it posts on social media and other communication channels listed on its website.

Forward-Looking Statements

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “look forward to,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include, among others, statements regarding: the expected DC RFS dates and the expected IT capacity of each data center identified above, and the aggregate AI Cloud capacity figures presented in this press release, including total campus capacity; the GPU platforms expected to be deployed at each facility and the availability and timing of delivery of that equipment; the expected commencement of revenue recognition in the first quarter of 2027 and the total expected revenue of more than $800 million under the A102 contracts; the manner in which Bitdeer AI seeks to structure its AI Cloud contracts, including expected customer prepayment coverage; the total contract value of the Tydal lease over the initial 16-year base term and the potential total contract value of approximately $8.0 billion if the tenant exercises its one-time 8-year extension option; the expected performance and characteristics of the Tydal data center, including its expected PUE and use of renewable energy; the initial 30 MW of capacity and the potential 500 MW expansion pathway contemplated by the non-binding letter of intent in Bhutan; the Company’s expectations regarding additional power allocations at its Rockdale site; the expected deployment of GPU hardware at the A201 facility; the outcome of ongoing contract negotiations, including in respect of the A201 facility; and the expectation of continued momentum in the Company’s mining results. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the section entitled “Risk Factors” in Bitdeer’s annual report on Form 20-F, as well as discussions of potential risks, uncertainties, and other important factors in Bitdeer’s subsequent filings with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof. Bitdeer specifically disclaims any obligation to update any forward-looking statement, whether due to new information, future events, or otherwise. Readers should not rely upon the information on this page as current or accurate after its publication date.

For investor and media inquiries, please contact:

Investor Relations
Tesh Dahya, Head of Investor Relations
tesh.dahya@bitdeer.com

Media
Elev8 New Media
Jessica Starman, MBA
bitdeer@elev8newmedia.com

GLENVILLE, N.Y., Sept. 16, 2026 (GLOBE NEWSWIRE) — The Board of Directors (the “Board”) of TrustCo Bank Corp NY (the “Company”) (Nasdaq: TRST) on September 15, 2026 announced the election of Patricia Kieper-Fusco and Bryan L. Guentner to the Company’s Board. The pair also was elected to the board of directors of Trustco Bank, the Company’s wholly-owned subsidiary. The elections are effective immediately.

Patricia Kieper-Fusco is the President, Chief Executive Officer, and Owner of Fusco Personnel, Inc. of Latham, New York. Her firm provides staffing, recruiting, and search services. Ms. Kieper-Fusco is also a member of the board of directors of the Capital Region Chamber of Commerce, is a former member of the board of directors of Ronald McDonald Charities of the Capital Region, and she is active in numerous other charitable and business-centered groups. She previously served on the Trustco Bank Advisory Board of Directors.

Bryan L. Guentner is a broker associate with RE/MAX Palm Realty in Sarasota, Florida and is the former owner and Chief Executive Officer of RE/MAX Platinum Realty also in Sarasota, Florida. Mr. Guentner is the former President of Siesta Key Chamber of Commerce and the Osprey-Nokomis Chamber of Commerce. He is also a realtor emeritus with the National Association of Realtors and has been active with numerous other business and community groups. He also served as a member of the Trustco Bank Advisory Board of Directors.

Chairman, President, and Chief Executive Officer Robert J. McCormick made the announcement, saying: “We are very pleased to announce the addition of these two fine business people to our Board. Patty brings experience in the area of human resources – an area of critical importance to every business. Bryan brings vast and deep knowledge of real estate markets on the West Coast of Florida. Trustco Bank has been very successful in that area, and Bryan’s experience will serve the bank well.”

About TrustCo Bank Corp NY

TrustCo Bank Corp NY is a $6.5 billion savings and loan holding company and through its subsidiary, Trustco Bank, operated 133 offices in New York, New Jersey, Vermont, Massachusetts, and Florida.

In addition, the Bank’s Wealth Management Department offers a full range of investment services, retirement planning and trust and estate administration services. The common shares of TrustCo are traded on the NASDAQ Global Select Market under the symbol TRST.

Forward-Looking Statements

All statements in this news release that are not historical are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future developments, results or periods. Examples of forward-looking statements include, among others, statements we make regarding our expectations regarding the impact that our new directors will have on the bank. Forward-looking statements are based on management’s current expectations as well as certain assumptions and estimates made by, and information available to, management at the time the statements are made. TrustCo wishes to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made and which are subject to factors and uncertainties that could cause actual results to differ materially for TrustCo from the views, beliefs and projections expressed in or implied by such statements, including but not limited to, risks and uncertainties relating to our dependency on the services of our management team external economic factors, such as changes the interest rate policies of the Federal Reserve Board and other changes in monetary policy, as well as ongoing inflationary pressures and continued elevated prices; the risk of weakness in residential real estate markets; the risks and uncertainties set forth under the heading “Risk Factors” in our most recent Annual Report on Form 10-K for the year ended December 31, 2025, and, if any, our subsequent Quarterly Reports on Form 10-Q; the financial, operational and legal risks and uncertainties detailed from time to time in TrustCo’s filings with the Securities and Exchange Commission, including within the cautionary statements contained in such filings; and the effect of all of such items on our operations, liquidity and capital position, and on the financial condition of our borrowers and other customers. The forward-looking statements contained in this news release represent TrustCo management’s judgment as of the date of this news release. TrustCo disclaims, however, any intent or obligation to update forward-looking statements, either as a result of future developments, new information or otherwise, except as may be required by law.

Subsidiary: Trustco Bank

Contacts:	Robert M. Leonard
	Executive Vice President and
	Chief Operating Officer
	(518) 381-3693
	Lauren A. McCormick
	Vice President, Treasurer, and
	Assistant Corporate Secretary
	(518) 381-3673

WAUSAU, Wis., Sept. 16, 2026 (GLOBE NEWSWIRE) — PSB Holdings, Inc. (OTCQX: PSBQ), parent company of Peoples State Bank, is pleased to announce that on September 15, 2026, its Board of Directors declared a regular quarterly cash dividend of $0.18 per share of the Company’s common stock. The dividend is payable on October 30, 2026, to shareholders of record as of October 8, 2026. The current dividend continues a 61-year tradition of cash dividends to PSB shareholders.

PSB Holdings President and CEO Scott M. Cattanach said, “PSB leadership has been proud to consistently grow and pay shareholder dividends for many years as an important part of our shareholder value. Our merger partner, Bank First Corporation, has a similar focus on rewarding shareholders with dividends and is a good fit for our shareholders, as well as for our customers. Our shareholders’ next quarterly dividend for the December 2026 quarter is expected to occur after the closing of our merger and will be determined by Bank First Corporation as part of their normal governance process.”

About PSB Holdings, Inc.

PSB Holdings, Inc. is the parent company of Peoples State Bank. Peoples is a community bank headquartered in Wausau, Wisconsin, serving northcentral and southeastern Wisconsin from twelve full-service banking locations in Marathon, Oneida, Vilas, Portage, Milwaukee and Waukesha counties. Peoples also provides investment and insurance products, along with retirement planning services, through Peoples Wealth Management, a division of Peoples. PSB Holdings, Inc. is traded under the stock symbol PSBQ on the OTCQX Market. More information about PSB, its management, and its financial performance may be found at www.psbholdingsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations, estimates and projections about PSB’s business based, in part, on assumptions made by management and include, without limitation, statements with respect to the potential growth of PSB, its future profits, expected stock repurchase levels, future dividend rates, future interest rates, and the adequacy of its capital position. Forward-looking statements can be affected by known and unknown risks, uncertainties, and other factors, including, but not limited to, strength of the economy, the effects of government policies, including interest rate policies, risks associated with the execution of PSB’s vision and growth strategy, including with respect to current and future M&A activity, and other risks. The forward-looking statements in this press release speak only as of the date on which they are made and PSB does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release.

Investor Relations Contact
PSB Holdings, Inc.
1905 Stewart Avenue
Wausau, WI 54401
888.929.9902
InvestorRelations@bankpeoples.com